Table 3.

Associations between baseline lipoproteins and the composite end point of ESRD or 50% decline in GFR in the Chronic Renal Insufficiency Cohort study

LipoproteinUnadjustedAdjusteda
Hazard Ratiob (95% CI)P ValueHazard Ratiob (95% CI)P Value
Total cholesterol1.15 (1.08 to 1.23)<0.011.00 (0.93 to 1.07)0.98
LDL cholesterol1.01 (0.95 to 1.08)0.680.95 (0.89 to 1.02)0.14
HDL cholesterol0.87 (0.81 to 0.93)<0.011.00 (0.92 to 1.08)0.95
VLDL cholesterolc1.33 (1.25 to 1.42)<0.011.06 (0.99 to 1.14)0.11
Triglyceridesc1.26 (1.19 to 1.34)<0.011.05 (0.97 to 1.12)0.21
Lp(a)c1.26 (1.18 to 1.35)<0.011.07 (0.99 to 1.15)0.09
ApoA-I0.93 (0.87 to 1.00)0.041.01 (0.93 to 1.10)0.75
ApoB1.23 (1.15 to 1.30)<0.011.00 (0.94 to 1.07)0.95
  • Lp(a), lipoprotein(a).

  • a Model adjusted for age, race, sex, diabetes, BP, statin use at baseline, smoking, 24-hour urine protein excretion, body mass index, clinical center, alcohol use, and baseline eGFR.

  • b Hazard ratios reported as per 1-SD change in independent variable.

  • c Values were log transformed.